(Q46552205)

English

Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.

scientific article published on 6 June 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18538834%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18538834%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

Barbara A. Goff

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18538834%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Brenda F. Kurland

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18538834%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Leona A Holmberg

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18538834%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Dan Veljovich

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18538834%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Puget Sound Oncology Consortium

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18538834%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

language of work or name

0 references

publication date

6 June 2008

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18538834%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18538834%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

110

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18538834%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18538834%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

146-151

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18538834%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.037

7 January 2021

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.037

7 January 2021

Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.037

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.037

7 January 2021

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.037

7 January 2021

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.037

7 January 2021

A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.037

7 January 2021

A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.037

7 January 2021

Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.037

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.037

7 January 2021

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.037

7 January 2021

Reliability and validity of the functional assessment of cancer therapy-ovarian.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.037

7 January 2021

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.037

7 January 2021

Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.037

7 January 2021

Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.037

7 January 2021

A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.037

7 January 2021

A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.037

7 January 2021

A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.037

7 January 2021

Combined Therapy with Topotecan and Gemcitabine in Patients with Inoperable or Metastatic Non-small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.037

7 January 2021

Identifiers

10.1016/J.YGYNO.2008.04.037

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18538834%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18538834%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46552205&oldid=1372428208"